AUS
NZ
UK
CA
USA
IND
The below mentioned health care stocks have reported loss for six months ended 31 December 2019. Letâs take a closer look at these stocks-
Imugene Limited (ASX:IMU)
The biotechnology company, Imugene Limited (ASX:IMU) recently disclosed that it had received and accepted the minutes of its Pre-Investigational New Drug meeting with the US Food and Drug Administration for its KEY-Vaxx cancer immunotherapy on 8 February 2019. During the meeting, the companyâs team met with 7-member panel of the FDA Division who guided the companyâs team for successful IND submission. For the half-year ended 31 December 2018, the company reported a loss of $3.449 million, driven by the significant increase in clinical trial and research activities undertaken by the group.
The stock price of Imugene Limited declined by 13.64% in the past 6 months and last traded at $0.019 with a market capitalization of ~$68.59 million as on March 22th, 2019.
BTC Health Ltd (ASX:BTC)
Australian speciality biopharmaceutical company, BTC Health Ltd (ASX:BTC) recently reported revenue from ordinary activities of $105K for the six months ended 31 December 2018, which is 14.23% higher than the previous corresponding period (pcp). For the half-year period, the company made a loss after tax of $245,587 as compared to the loss of $1,389,124 in pcp, driven by the prior year impairment of the investment and the outstanding loan in Biointelect Pty Ltd. As part of its growth plan, the company is planning to establish a broader set of organizational capabilities. Further, the company intends to build a strong pipeline of medical product opportunities. The company is evaluating and negotiating potentially transformative acquisition opportunities.
The share price of BTC Health Ltd declined by 34.29 percent in the past six months and last traded at $0.115 with a market capitalization of ~$14.98 million as on 22 March 2019.
Biotron Limited (ASX:BIT)
Biotron Limited (ASX:BIT) is publicly listed Australian Biotechnology Company. The company is primarily involved in the development for the treatment of HIV-1 and Hepatitis C virus infection. For the half-year period, the company reported revenue from ordinary activities of $18,372 which was 92.98% higher than the corresponding previous period (pcp). Further, the company reported a loss from ordinary activities of $261,133 which was 63.41% higher than pcp.
During the half year period, the company released positive human clinical data from its BIT225-009 Phase 2 trial which was a major highlight of the first half of FY 2019. With positive results from its clinical trials, the company is focused on achieving a commercial outcome for its antiviral programs.
The share price of the company decreased by 22.61% in the past 3-months period and last traded at $0.089 with a market capitalization of circa 52.99 million as on 22 March 2019.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.